Latest MediciNova News & Updates

See the latest news and media coverage for MediciNova. We track all announcements, press releases, and industry mentions in real time, all in one place.

MediciNova

Biopharmaceutical company focused on neurology, respiratory, and liver diseases

medicinova.com

Headquarters: La Jolla, United States
Company type: Public company
Number of employees: 16–50
Industry: Pharmaceuticals

Last updated October 29

Latest news about MediciNova

In short: MediciNova completed MN-166 ALS trial enrollment, reported positive MN-001 results, and advanced its pipeline.

Company announcements

October 7 MediciNova

MediciNova CEO updates shareholders on MN-001 trial and MN-166 ALS progress

CEO Yuichi Iwaki shares results from the Phase 2 MN-001 NAFLD trial and announces completion of patient enrollment for the COMBAT-ALS study.

September 28 MediciNova

MediciNova reports positive MN-001 clinical trial results

The Phase 2 trial showed significant HDL increases and triglyceride reductions for MN-001 treating metabolic conditions with good safety.

July 31 MediciNova

MediciNova completes enrollment of 200 patients in ALS study

The SEANOBI-ALS trial for MN-166 (ibudilast) reached full enrollment, advancing potential new treatment for ALS.

June 30 MediciNova

MediciNova CEO updates shareholders on clinical milestones

MN-001 Phase 2 trial completed, MN-166 patent allowed, ALS enrollment at 50%.

Media coverage

October 29 Ad Hoc News

MediciNova stock: MN-001 shows signals but misses primary endpoints

MediciNova said on October 12, 2026, that its Phase 2 study of MN-001 produced encouraging signals in metabolic disease but did not achieve statistical significance...

September 28 La Verdad

Eduardo Osuna takes office as dean of the Faculty of Medicine at the University of Murcia | La Verdad

Numerous members of... attended the event, which was held in the Virgen de la Arrixaca Teaching Pavilion, on the Health Sciences campus.

September 24 Santé log

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

The trial’s primary endpoint is the Combined Assessment of Function and Survival (CAFS). Secondary endpoints include change in the ALS Functional Rating Scale–Revised (ALSFRS-R), muscle...

September 17 Benzinga

MediciNova (MNOV) Stock Price, Quote, News & History | Benzinga

Why Is It Moving?™:MediciNova shares are trading higher after Roth Capital initiated coverage ... Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV...

Never miss news about MediciNova

Track MediciNova and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

MediciNova competitors & trending companies

Browse news for competitors to MediciNova and other trending companies.